go-v.orgcodex
Menu
Page tools

codex · Chemistry

Evofosfamide

Diagram for Evofosfamide
Evofosfamide (development code TH-302) is an investigational new drug that is being evaluated for the treatment of multiple tumor types, including pancreatic cancer, soft tissue sarcoma, and multiple myeloma, often in combination with other therapies. It is a hypoxia-activated prodrug designed to ta · image: Wikimedia Commons

Evofosfamide (development code TH-302) is an investigational new drug that is being evaluated for the treatment of multiple tumor types, including pancreatic cancer, soft tissue sarcoma, and multiple myeloma, often in combination with other therapies. It is a hypoxia-activated prodrug designed to target and kill hypoxic cells within tumors. It functions by releasing the DNA crosslinking agent bromo-isophosphoramide mustard under low oxygen conditions, making it potentially effective against tumor regions where standard chemotherapy and radiation therapies are less effective due to hypoxia. Commercialization has not been pursued due to the failure of several clinical trials.

Wikipedia contributors, "Evofosfamide", Wikipedia, revision 1382918673, retrieved 20 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex